Abbott Laboratories Director Kevin T. Conroy Receives Restricted Stock Units

This SEC Form 4 filing reports that Kevin T. Conroy, a director of Abbott Laboratories, received 2,286 restricted stock units on April 24, 2026. The award was granted under the Abbott Laboratories 2026 Incentive Stock Program and will be paid in Abbott common shares on a one-to-one basis upon the earlier of the director's separation from service, death, or a change in control event. The transaction price per share was $0.00, which is typical for restricted stock unit awards. Following this transaction, Conroy's total holdings in Abbott Laboratories common shares increased to 133,737 shares. The filing was signed by Jessica H. Paik as attorney-in-fact for Kevin T. Conroy on April 28, 2026. This represents a routine equity compensation award to a corporate director as part of Abbott's incentive program.